When targeted to T cell subsets, this IL-2 variant could be clinically translated in the context of controlling T-cell mediated (auto)immune disorders where it is essential to prevent effector T cell activation and expansion resulting in effector cell-mediated tissue damage, such as during acute GvHD. Here, IL2 is linked to graft versus host disease.